Volume 7: Issue 3

SCCOR Investigators: Paul M. Hassoun: overall Principal Investigator, Project 1 leader and administrative core leader; Hunter C. Champion: Project 2 leader; Fredrick Wigley: Project 3 leader; Roger A. Johns: Project 4 leader; Michael Crow: Project 5 leader; Noah Lechtzin: data management and statistics; Allen Myers: pathology core; Kathleen C. Barnes: genetics/genomics core; Jennifer van Eyk: proteomics core; and Jens Vogel-Claussen: imaging core.

SCCOR Investigators: John Kinsella: Principal Investigator (PI) Project 1; Robin Shandas, PI, Dunbar Ivy, Co-PI: Project 2; Kurt Stenmark. PI: Project 3; Carl White, PI: Project 4.

Ivan F. McMurtry, PhD

Download as Powerpoint
Download Figure

Based on differences in clinical presentation, diagnostic findings, and response to treatment, human pulmonary hypertension (PH) has been subdivided into 5 categories. These include1:

Pulmonary arterial hypertension (PAH)
PH with left-sided heart disease
PH associated with respiratory disorders and/or hypoxemia
PH caused by chronic thrombotic and/or embolic disease
PH caused by miscellaneous other disorders affecting the pulmonary vasculature.

The PAH category encompasses the idiopathic and familial forms of PH as well as those that occurr secondarily to several other diseases or conditions, including connective tissue disease, congenital systemic-to-pulmonary shunts,

This roundtable discussion, reviewing the proceedings from the Pulmonary Hypertension Association's Eighth International PH Conference and Scientific Sessions in Houston in 2008, was moderated by Karen Fagan, MD, Chief, Division of Pulmonary and Critical Care Medicine, University of South Alabama, Mobile, Alabama. It included Todd Bull, MD, Associate Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Health Sciences Center, Aurora, Colorado; Ivan F. McMurtry, PhD, Professor, Department of Pharmacology, University of South Alabama School of Medicine, Mobile, Alabama; and Omar A. Minai, MD, Staff Physician in the Department of Pulmonary, Allergy, and Critical Care Medicine and the Lung Transplant Center at the Cleveland Clinic, Cleveland, Ohio.

Editor's Memo

From PHA's Scientific Sessions, a Time for Reflection on the Progress Toward a Cure

The Scientific Leadership Council of the Pulmonary Hypertension Association

In a Remarkably Short Time, Vallerie McLaughlin, MD, Joins a Select Group of Investigators Blazing a Trail in PH Research

The Metabolic Syndrome and Cardiac Function

Specialized Centers of Clinically Oriented Research Programs in Pulmonary Hypertension Reported Progress at the PHA Scientific Sessions

National Heart Lung and Blood Institute Hopkins Specialized Center in Clinical Oriented Research (SCCOR): Molecular Determinants of Pulmonary Arterial Hypertension

Specialized Center in Clinical Oriented Research (SCCOR) Update: Mechanisms and Treatment of Lung Vascular Disease in Infants and Children

Getting More From Right Heart Catheterization: A Focus on the Right Ventricle

Animal Models of Human Severe PAH

PHA Scientific Sessions Provide a Great Window Into Treatment Breakthroughs While Inspiring Physicians and Patients Alike

Connective Tissue Disease-Associated Pulmonary Hypertension

Conference Abstracts

Guest Editor’s Memo

A Roundtable Discussion Addressing Patient-Centered Care and Quality of Life in Patients With Pulmonary Arterial Hypertension

Editor’s Memo

Pulmonary Hypertension Associated With Parenchymal Lung Disease